CHMP Backs Hansoh Pharma’s Aumolertinib – China’s First Homegrown Third‑Generation EGFR‑TKI Recommended for EU Approval in NSCLC

Hansoh Pharmaceutical Group (HKG: 3692) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of aumolertinib (overseas trade name: Aumseqa) for the treatment of…

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.

More News